1. Epigenetics
  2. Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides), which triggers the RNA interference (RNAi) pathway. The short dsRNA unwinds and the sense strand is degraded. Antisense strand forms RNA induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC has nuclease activity, which can cut and degrade the target gene mRNA, and inhibit the expression of target gene. Incomplete complementarity results in mRNA translation inhibition.

Small Interfering RNA (siRNA) Related Products (28):

Cat. No. Product Name Effect Purity
  • HY-132589
    Vutrisiran
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research[1].
  • HY-150150
    SiRNA Negative Control
    SiRNA Negative Control is a siRNA of 21 nucleotides, and can be used as a negative control.
  • HY-132596
    Tivanisiran
    Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1)[1].
  • HY-132591
    Inclisiran
    Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research[1].
  • HY-132610
    Givosiran
    Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria[1][2].
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research[1].
  • HY-153609
    AS-Patisiran
    Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis[1][2][3].
  • HY-150224
    GalNAc unconjugated/naked Fitusiran
    GalNAc unconjugated/naked Fitusiran, an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. GalNAc unconjugated/naked Fitusiran increases thrombin generation and has the potential for the research of the hemophilia[1].
  • HY-132606
    Nedosiran
    Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate[1][2][3].
  • HY-147425
    Zerlasiran
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer[1].
  • HY-132613
    Lumasiran sodium
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) [1][2].
  • HY-153484A
    Bevasiranib sodium
    Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
  • HY-147266
    Elebsiran
    Elebsiran is an antiviral agent[1].
  • HY-132588
    Lumasiran
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1)[1][2].
  • HY-153492
    Olpasiran
    Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver.
  • HY-153485
    Cimdelirsen
    Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
  • HY-132609
    Patisiran sodium
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis[1][2][3].
  • HY-132587
    Fitusiran
    Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia[1].
  • HY-153484
    Bevasiranib
    Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
  • HY-132604
    Fazirsiran
    Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade AAT mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes[1].